News & Videos - BLUE BIRD CORP.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE PR Newswire NEW YORK, March 11, 2025 NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether bluebird and certain of its officers and/or...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE PR Newswire NEW YORK, March 3, 2025 NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether bluebird and certain of its officers and/or...

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, highlights its latest zero- and ultra-low emission commercial vehicle solutions at the upcoming Work Truck Week 2025 ( WTW25 ). The company debuts its groundbreaking propane-powered Class 5-6 stripped chassis. In addition, Blue Bird presents its state-of-the-art electric step van at the show’s Ride & Drive. WTW25 takes place on March 4–7, 2025, at the Indiana Convention Center in Indianapolis, Ind....

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird’s current product portfolio...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc. PR Newswire NEW YORK, Feb. 21, 2025 NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning the proposed acquisition of the company by Carlyle (NASDAQ: CG) and SK Capital Partners, LP. Stockholders will receive $3.00 and a contingent value right of $6.84 for each share of bluebird bio...

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE PR Newswire NEW YORK, Feb. 21, 2025 NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating bluebird bio, Inc. (Nasdaq: BLUE ) ,...

Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital . Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, bluebird stockholders will receive only $3.00 per share in cash and a contingent value right per share,...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if bluebird’s current product portfolio achieves $600 million in net sales in any trailing...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird primary capital to scale...

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, donated an advanced electric school bus to Hoop Bus Inc, a 501(c)(3) nonprofit organization dedicated to youth programming and community engagement across North America. The full-size, zero-emission bus is equipped with basketball hoops at the front and back, turning the vehicle into an interactive, mobile court. Hoop Bus will use this electric vehicle to serve thousands of at-risk youth in...

Blue Bird Corporation (“Blue Bird”) (Nasdaq: BLBD), the leader in electric and low-emission school buses, announced today its fiscal 2025 first quarter results. Highlights (in millions except Unit Sales and EPS data) Three Months Ended December 28, 2024 B/(W) Prior Year Unit Sales 2,130 1 GAAP Measures: Revenue $ 313.9 $ (3.8 ) Net Income $ 28.7 $ 2.6 Diluted EPS $ 0.86 $ 0.05 Non-GAAP Measures 1 : Adjusted EBITDA $ 45.8 $ (1.9 ) Adjusted Net Income $ 30.6 $ 0.9 Adjusted Diluted EPS $ 0.92 $...

Glades County School District (GCSD) has introduced 13 industry-leading electric school buses to its fleet for the 2024-2025 school year. The new electric school buses will replace more than half of the district's outdated diesel buses—some of which have been in operation for more than 25 years. The district will now benefit from the cleaner, quieter rides and cost savings that electric school buses provide. In addition, all new electric buses offer much-needed air conditioning. Until now,...

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, has appointed John Wyskiel to the position of President and CEO, effective February 17, 2025. He will also join the Board of Directors on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122110592/en/ Blue Bird appointed automotive industry veteran John Wyskiel to President and CEO. (Photo: Business Wire) Wyskiel succeeds Phil...

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and cleaner-emission school buses, will release its fiscal 2025 first quarter results on February 5, 2025. The public is invited to attend an audio webcast in which Blue Bird executives Phil Horlock, President and CEO, and Razvan Radulescu, CFO, will discuss results. This webcast will take place at 4:30PM ET on February 5, 2025. A slide presentation will be available to support the webcast. Dial-in details and the webcast of the...

Wilkes County Schools (WCS) has marked the historic milestone of becoming the first school district in Georgia to serve all of its 25 daily bus routes exclusively with zero- and ultra-low-emission school buses. WCS’ new fleet of electric and propane-powered buses eliminates regular diesel bus routes, significantly improving air quality for students and the surrounding community, while also significantly reducing operating costs. This press release features multimedia. View the full release...

bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral presentation on Sunday, December 8 at 9:30 a.m. Pacific Time and a poster presentation on Sunday, December 8 at 6 p.m. Pacific Time. As of July 2024,...

bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66 th American Society of Hematology (ASH) Annual Meeting and Exposition. “Updated follow-up data of up to 10 years showed that patients treated with beti-cel in clinical trials experienced durable transfusion...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced, the primary goal of the Reverse Stock Split is to increase the per share market price of the Company’s common stock to regain...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events (VOEs). “Ensuring timely, equitable access to gene therapy for...

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, lauds the U.S. expansion of Micro Bird’s manufacturing operations to build small and midsize buses in New York State. Micro Bird, a 50/50 joint venture of Blue Bird Corporation and Girardin, has confirmed the purchase of the Nova Bus facility in Plattsburgh, NY, and plans to begin production in mid-2025. The investment will enable Micro Bird to double its production capacity to better meet the sustained...